Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction

Edward Kim, Kevin T. McVary

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

This study was undertaken as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of topical prostaglandin-E1 for the treatment of erectile dysfunction. Nine men with erectile dysfunction secondary to spinal cord injury and 1 man with mild arterial insufficiency were enrolled in the trial and underwent color flow Doppler ultrasound of the penis after application of topical prostaglandin-E1 to the penis, scrotum and perineum. Eight men completed all phases of the study. Mean cavernous artery diameter increased from 0.09 to 0.11 cm. (p less than 0.05) and mean peak systolic flow velocity increased from 15.4 to 22.8 cm. per second (p less than 0.05) using color flow Doppler ultrasound. Peak systolic flow velocity increased in both cavernous arteries in 7 of 10 patients. Clinical erections were observed in 2 patients but they were not present with placebo application. Diastolic blood pressure and heart rate varied after application of prostaglandin-E1 to the genitalia. No patient was symptomatic and no adverse skin effects were observed in the 8 patients completing all phases of the study. In conclusion, topical prostaglandin-E1 appears to be safe and well tolerated after application to the genitalia, and significantly increases blood flow to the penis. Further investigation is being pursued.

Original languageEnglish (US)
Pages (from-to)1828-1830
Number of pages3
JournalThe Journal of Urology
Volume153
Issue number6
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Alprostadil
Erectile Dysfunction
Penis
Doppler Ultrasonography
Genitalia
Arteries
Color
Placebos
Blood Pressure
Perineum
Scrotum
Therapeutics
Spinal Cord Injuries
Heart Rate
Safety
Skin

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction. / Kim, Edward; McVary, Kevin T.

In: The Journal of Urology, Vol. 153, No. 6, 01.01.1995, p. 1828-1830.

Research output: Contribution to journalArticle

Kim, Edward ; McVary, Kevin T. / Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction. In: The Journal of Urology. 1995 ; Vol. 153, No. 6. pp. 1828-1830.
@article{06bc682d61b8482a8b93133d2b1bd0a8,
title = "Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction",
abstract = "This study was undertaken as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of topical prostaglandin-E1 for the treatment of erectile dysfunction. Nine men with erectile dysfunction secondary to spinal cord injury and 1 man with mild arterial insufficiency were enrolled in the trial and underwent color flow Doppler ultrasound of the penis after application of topical prostaglandin-E1 to the penis, scrotum and perineum. Eight men completed all phases of the study. Mean cavernous artery diameter increased from 0.09 to 0.11 cm. (p less than 0.05) and mean peak systolic flow velocity increased from 15.4 to 22.8 cm. per second (p less than 0.05) using color flow Doppler ultrasound. Peak systolic flow velocity increased in both cavernous arteries in 7 of 10 patients. Clinical erections were observed in 2 patients but they were not present with placebo application. Diastolic blood pressure and heart rate varied after application of prostaglandin-E1 to the genitalia. No patient was symptomatic and no adverse skin effects were observed in the 8 patients completing all phases of the study. In conclusion, topical prostaglandin-E1 appears to be safe and well tolerated after application to the genitalia, and significantly increases blood flow to the penis. Further investigation is being pursued.",
author = "Edward Kim and McVary, {Kevin T.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(01)67323-3",
language = "English (US)",
volume = "153",
pages = "1828--1830",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction

AU - Kim, Edward

AU - McVary, Kevin T.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - This study was undertaken as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of topical prostaglandin-E1 for the treatment of erectile dysfunction. Nine men with erectile dysfunction secondary to spinal cord injury and 1 man with mild arterial insufficiency were enrolled in the trial and underwent color flow Doppler ultrasound of the penis after application of topical prostaglandin-E1 to the penis, scrotum and perineum. Eight men completed all phases of the study. Mean cavernous artery diameter increased from 0.09 to 0.11 cm. (p less than 0.05) and mean peak systolic flow velocity increased from 15.4 to 22.8 cm. per second (p less than 0.05) using color flow Doppler ultrasound. Peak systolic flow velocity increased in both cavernous arteries in 7 of 10 patients. Clinical erections were observed in 2 patients but they were not present with placebo application. Diastolic blood pressure and heart rate varied after application of prostaglandin-E1 to the genitalia. No patient was symptomatic and no adverse skin effects were observed in the 8 patients completing all phases of the study. In conclusion, topical prostaglandin-E1 appears to be safe and well tolerated after application to the genitalia, and significantly increases blood flow to the penis. Further investigation is being pursued.

AB - This study was undertaken as a phase I, placebo controlled, nonblinded investigation of the safety and efficacy of topical prostaglandin-E1 for the treatment of erectile dysfunction. Nine men with erectile dysfunction secondary to spinal cord injury and 1 man with mild arterial insufficiency were enrolled in the trial and underwent color flow Doppler ultrasound of the penis after application of topical prostaglandin-E1 to the penis, scrotum and perineum. Eight men completed all phases of the study. Mean cavernous artery diameter increased from 0.09 to 0.11 cm. (p less than 0.05) and mean peak systolic flow velocity increased from 15.4 to 22.8 cm. per second (p less than 0.05) using color flow Doppler ultrasound. Peak systolic flow velocity increased in both cavernous arteries in 7 of 10 patients. Clinical erections were observed in 2 patients but they were not present with placebo application. Diastolic blood pressure and heart rate varied after application of prostaglandin-E1 to the genitalia. No patient was symptomatic and no adverse skin effects were observed in the 8 patients completing all phases of the study. In conclusion, topical prostaglandin-E1 appears to be safe and well tolerated after application to the genitalia, and significantly increases blood flow to the penis. Further investigation is being pursued.

UR - http://www.scopus.com/inward/record.url?scp=0029043759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029043759&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)67323-3

DO - 10.1016/S0022-5347(01)67323-3

M3 - Article

VL - 153

SP - 1828

EP - 1830

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -